Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Viet Tran

Clinical Cardiac Electrophysiology Chandler, AZ Medical Doctor

NPI 1235465311 CMS profile 283352

1125 S Alma School Rd Ste 310, Ste 5008, Chandler, AZ 85286

Open in the dashboard

General payments

$46,987

374 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Viet Tran of Chandler, AZ is reported in the CMS Open Payments database as having received $46,987 across 374 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,034 35
2024 General $3,306 27
2023 General $16,111 57
2022 General $5,710 97
2021 General $2,223 47
2020 General $3,289 46
2019 General $13,314 65

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Viet Tran
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Viet Tran were reported at $3,034. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Viet Tran Clinical Cardiac Electrophysiology median Middle half National median
2019 $13,314 $2,361 $585–$8,260 $163
2020 $3,289 $993 $247–$4,351 $114
2021 $2,223 $1,185 $326–$4,739 $132
2022 $5,710 $2,073 $554–$6,789 $149
2023 $16,111 $2,568 $759–$8,159 $160
2024 $3,306 $2,557 $703–$7,403 $164
2025 $3,034 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $15,457 109 payments
  2. Medical Device Business Services, Inc. $14,247 4 payments
  3. Abbott Laboratories $10,023 106 payments
  4. Biosense Webster, Inc. $1,882 35 payments
  5. Biotronik Inc. $1,366 14 payments
  6. Medtronic, Inc. $629 4 payments
  7. Impulse Dynamics (USA) Inc. $533 25 payments
  8. Philips Electronics North America Corporation $406 7 payments
  9. Acutus Medical, Inc. $393 3 payments
  10. Medtronic Vascular, Inc. $340 3 payments
  11. Other $1,711 64 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $17,943 319 payments
  2. Consulting Fee $11,588 4 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $11,550 33 payments
  4. Travel and Lodging $5,907 18 payments
Products named General payments · program years 2019–2025
  1. Carto 3 $15,006 21 payments
  2. RHYTHMIA $4,372 18 payments
  3. EMBLEM $3,750 10 payments
  4. EMBLEM S ICD ELECTRODE DELIVERY SYSTEM $3,000 8 payments
  5. Quadra Assura CRT Defibrillator $1,681 15 payments
  6. AVEIR Cardiac Rhythm Management $1,317 14 payments
  7. AVEIR Structural Heart $1,276 9 payments
  8. WATCHMAN Access System $954 10 payments
  9. ENSITE $821 7 payments
  10. GALLANT $805 7 payments
  11. Other $13,394 264 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,180

Median for Cardiology: 2,533

Drug cost

$336,967

Median for Cardiology: $485,213

Branded share of claims

30.3%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 172 $208,011
Xarelto Rivaroxaban Brand 57 $59,948
Entresto Sacubitril/Valsartan Brand 50 $57,649
Metoprolol Succinate Generic 157 $2,232
Amiodarone Hcl Generic 72 $1,013
Flecainide Acetate Generic 34 $755
Atorvastatin Calcium Generic 57 $732
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 29 $674
Midodrine Hcl Generic 14 $658
Carvedilol Generic 38 $656

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 76 billing codes

Paid by Medicare

$144,712

Of which drugs: $751

Medicare patients

570

Average age 75

Services billed

1,904

283 women, 287 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Ischemic heart disease 48%
Atrial fibrillation 48%
Chronic kidney disease 42%
Heart failure 41%
Diabetes 38%
Depression 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 13 52 $374

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

374 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record